With infusion data, repeated-measures analyses were carried out to assess the group difference simultaneously with the change over time in FFAs, blood glucose, insulin, C-peptide, and the C-peptide to glucose ratio (1).
Repeated measure analyses were carried out for weight, nutritional status and global QoL using SPSS version 10, 2000 (SPSS Inc., Chicago, IL, USA).
All behavioral, anatomical, and biochemical measures and analyses were carried out with a blinded experimental design according to published guidelines.
To explore the impact of unknown stage at diagnosis on model fit and summary measures, sensitivity analyses were carried out by repeating the all-cause and CRC-specific survival analyses under three different assumptions; (a) all unstaged cases being reclassified as Stage I, b) reclassified as Stage IV or c) equally distributed over all four stage categories.
In order to determine associations between haemoglobin concentration and any of the variables that we measured, regression analyses were carried out.
Correlations between fMRI and behavioral measures: several correlation analyses were carried out to explore the relationship between drug effects on imaging, weight change, BES scores, and eating behavior.
Postmortem analyses were carried out to measure indicators of malignancy, tumoural metabolism and viability of the blood-brain barrier (BBB).
To determine the extent of cell death, cell cycle analyses were carried out to measure the cellular DNA contents using a fluorescence-activated cell sorting (FACS /flow cytometry machine (BD), as previously described [13].
Univariate analyses were carried out to measure the association of each drug with IMDILI.
Statistical analyses were carried out on all measured variables.
Separate analyses were carried out for each exposure measure (in-utero and childhood exposure) where possible.
